Compare ANIP & AXGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANIP | AXGN |
|---|---|---|
| Founded | 2001 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 1999 | 2013 |
| Metric | ANIP | AXGN |
|---|---|---|
| Price | $72.10 | $32.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $107.33 | $37.63 |
| AVG Volume (30 Days) | 336.7K | ★ 796.8K |
| Earning Date | 05-11-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 419.23 | N/A |
| EPS | ★ 3.32 | N/A |
| Revenue | $206,547,000.00 | ★ $225,208,000.00 |
| Revenue This Year | $19.88 | $19.81 |
| Revenue Next Year | $15.77 | $16.31 |
| P/E Ratio | $21.19 | ★ N/A |
| Revenue Growth | 2.47 | ★ 20.21 |
| 52 Week Low | $56.71 | $9.22 |
| 52 Week High | $99.50 | $36.00 |
| Indicator | ANIP | AXGN |
|---|---|---|
| Relative Strength Index (RSI) | 38.93 | 54.51 |
| Support Level | $62.89 | $30.42 |
| Resistance Level | $85.12 | $34.26 |
| Average True Range (ATR) | 2.64 | 1.45 |
| MACD | -0.27 | 0.22 |
| Stochastic Oscillator | 25.10 | 79.15 |
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.